Criteria Bio Ventures: Investment Portfolio & Startup News
Criteria Bio Ventures
To add a bio or update investment portfolio, please click update information.
Investment Portfolio
Cytospire Therapeutics
5 May 2026
Cytospire Therapeutics secures £61m Series A led by 4BIO Capital for cancer therapies that activate the body’s immune cells
Cytospire Therapeutics develops multispecific immune cell engager antibodies designed to enhance and direct the activity of the body’s immune system. Its platform targets gamma delta T cells to generate anti tumour immune responses for patients with cancer and other diseases.
NRG Therapeutics
8 Sept 2025
NRG Therapeutics lands £50m Series B led by SV Health Investors to advance neurodegenerative disease therapies
NRG Therapeutics develops oral small-molecule drugs targeting mitochondrial dysfunction, aiming to slow or halt neurodegenerative diseases such as ALS and Parkinson’s through disease-modifying treatments.
Criteria Bio Ventures
More venture news
- 29 Sept 2026
DYADDYAD secures a £7.5m Series A led by Sangha Capital for its system that converts clinical documents into structured data for GP patient records
Series AHealth - 21 Sept 2026
SpriveSprive unlocks an £8m Series A from VCs to help homeowners pay down their mortgages
Series AFintech - 17 Sept 2026
MagenticMagentic closes £13m Series A led by Felicis to put AI workers inside the procurement teams of global manufacturers
Series ASupply Chain
